^
    Back
    Association details:
    Biomarker:TP53 mutation + ZFHX3 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Immunol
    Title:

    TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

    Published date:
    09/17/2021
    Excerpt:
    For patients harboring TP53(+), the top five upregulated genes (ZACNN: ZFHX3, ATM, CDKN2A, NOTCH4, and NTRK3) were selected as predictors for screening responders from non-responders. The results indicated that patients harboring ZACNN(+) received more OS benefits from immunotherapy than those harboring ZACNN(−) [ZACNN(+) vs. ZACNN(−) = undefined vs. 8 months, P < 0.0001]...
    DOI:
    https://doi.org/10.3389/fimmu.2021.732125
    Test:
    MSK-IMPACT
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Wiley Online Library
    Title:

    Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

    Published date:
    06/07/2021
    Excerpt:
    ...coexisting TP53 and ZFHX3 mutations were independent prognostic factors. Higher somatic TMB (highest 20% in each histology) and combination of anti-CTLA-4 and anti-PD-1/PD-L1 therapy were also associated with longer OS in multivariate analysis. Coexisting TP53 and ZFHX3 mutations are independent prognostic factors for advanced-stage NSCLC patients undergoing ICI treatment.
    DOI:
    10.1111/sji.13087